<DOC>
	<DOCNO>NCT01541072</DOCNO>
	<brief_summary>The purpose study describe kinetics lymphocyte subset reconstitution growth factor administration , Pegfilgrastim versus Filgrastim patient B-cell malignant non-Hodgkin lymphoma treat high-dose chemotherapy autologous peripheral stem cell transplantation .</brief_summary>
	<brief_title>Lymphocyte Reconstitution After Administration Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation</brief_title>
	<detailed_description>High dose chemotherapy autologous peripheral stem cell transplantation standard consolidation treatment use patient non-Hodgkin lymphoma , first second line treatment . This procedure associate prolong neutropenia considerable morbidity . Different guideline recommend use growth factor peripheral stem cell transplantation.Pegfilgrastim granulocyte colony-stimulating factor ( G-CSF ) result modification Filgrastim chemical addition polyethylene glycol ( PEG ) moiety increase half-life decrease renal clearance . Then , single injection substitute several Filgrastim injection . The trial `` PALM '' realize team show , 2 molecule , equivalent efficacy duration chemotherapy-induced febrile neutropenia patient treat lymphoma myeloma . This trial also show Pegfilgrastim cost-effectiveness dominant strategy . Some study show rapid lymphocyte reconstitution stem cell transplantation associate well overall survival progression-free survival . In present PALM2 study , investigator want describe kinetics different lymphocyte subset reconstitution within 3 6 month transplantation , patient B-cell malignant non-Hodgkin lymphoma , first second-line chemotherapy first autologous transplantation . The investigator assess kinetics reconstitution T-lymphocytes ( Naïve T-lymphocytes , regulatory T-cells memory T-cells ) , B-lymphocytes ( transitional B cell ) , cytotoxic T-cells natural killer T-cells , dendritic cell . A preliminary phase assessment consist estimate intra-center variability lymphocyte phenotyping .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Age ≥ 18 year . Patients Bcell NHL , except Burkitt Lymphoma primary brain lymphoma , firstline secondline therapy , plan BICNU , etoposide , aracytine melphalan ( BEAM ) chemotherapy preinclusion . Minimum one mobilization GCSF , GCSF endoxan mozobil Minimum one cytapheresis CD34 &gt; 2 million CD34/kg stem cell transplantation Patients hospitalize investigational center throughout procedure recovery aplasia ( neutrophils &gt; 0.5 G/L ) Mandatory affiliation health insurance system Subjects must provide write informed consent prior performance studyspecific assessment Patients already treat intensive chemotherapy autologous stem cell transplantation Total irradiation exposure ( patient partial irradiation exposure include study ) Intolerance one two studied growth factor , hypersensitivity one components Patients neutropenia ( neutrophil &lt; 1.2 G/L ) thrombopenia ( platelet &lt; 100 G/L ) intensive chemotherapy Acquired immune deficiency syndrome , seropositivity Pregnant lactate woman ( pregnancy test , woman childbearing potential , negative , blood urine , inclusion time ) Impossibility comply protocol constraint geographical , psychiatric , social family reason Deprived liberty ( court judgement administrative decision )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Lymphoma , B-cell</keyword>
	<keyword>Lymphocyte reconstitution</keyword>
	<keyword>Lymphocyte subset</keyword>
	<keyword>Peripheral stem cell transplantation</keyword>
	<keyword>Induction chemotherapy</keyword>
	<keyword>growth factor</keyword>
	<keyword>Granulocyte Colony-stimulating factor</keyword>
	<keyword>Pegfilgrastim</keyword>
	<keyword>Filgrastim</keyword>
</DOC>